Nucleix’s BE Safe @Home Project Brings Bladder Cancer Surveillance to Patients’ Homes During COVID-19 Pandemic and Beyond

SAN DIEGO & REHOVOT, Israel–(BUSINESS WIRE)–Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, recently announced the launch of its BE Safe @Home project to bring surveillance for recurrence of non-muscle invasive bladder cancer (NMIBC) to patients’ homes with its Bladder EpiCheck® urine test.

Subscribe to one of our social media channels